Compare Kota Satu Properti Tbk. (SATU) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kota Satu Properti Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Kota Satu Properti Tbk. trades at Rp246 (market cap 343.75B, 1.6M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Kota Satu Properti Tbk. is far larger — about 3.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SATU | SCPI | |
|---|---|---|
Market Cap | 343.75B | 104.4B |
Volume | 1.6M | — |
Lot | 16.02K | — |
Turnover | 401.74M | — |
Average Price | 250.71 | — |
Value | 401.74M | — |
Indicative Equilibrium Price | 246 | — |
Indicative Equilibrium Volume | 108 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kota Satu Properti Tbk.
PT Kota Satu Properti Tbk (the Company) was established based on Notarial Deed No. 6, dated October 3, 2012 of Maria Yosefa Deni, S.H., notary in Semarang. PT Kota Satu Properti Tbk. is a company the first developer and became a pioneer in introducing the modern housing concept in the city Ungaran, Semarang Regency. Where homeowners are surrounded by the convenience of modern facilities including: club house, lounge, swimming pool, kids playground, RFID gate system, panic button, CCTV & 24hours security, housekeeping & laundry, broadband internet (Wifi), ATMs and minimarkets.
Read more on SATU →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
